INFIQ (Infinity Pharmaceuticals) Cyclically Adjusted Revenue per Share: $1.15 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INFIQ Infinity Pharmaceuticals Inc INFIQ
16 GF Score
Price $0.00
View Full Analysis

What is Infinity Pharmaceuticals Cyclically Adjusted Revenue per Share?

Infinity Pharmaceuticals INFIQ -99.00% 16 Cyclically Adjusted Revenue per Share is $1.15 as of Jun. 2023. GuruFocus rates INFIQ with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Infinity Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2023 was $0.006. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.15 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-07), Infinity Pharmaceuticals's current stock price is $0.0001. Infinity Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $1.15. Infinity Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.00.


Infinity Pharmaceuticals  (OTCPK:INFIQ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Infinity Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.0001/1.15
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Infinity Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Infinity Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Infinity Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infinity Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.87 2.57 2.09 1.55 1.20

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 1.24 1.20 1.18 1.15

INFIQ vs CLCS, RVLPQ, IVRN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infinity Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


INFIQ
16GF Score
Infinity Pharmaceuticals Inc INFIQ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infinity Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Infinity Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.006/305.1090*305.1090
=0.006

Current CPI (Jun. 2023) = 305.1090.

Infinity Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.000 234.149 0.000
201312 0.000 233.049 0.000
201403 0.000 236.293 0.000
201406 0.000 238.343 0.000
201409 3.230 238.031 4.140
201412 0.089 234.812 0.116
201503 0.089 236.119 0.115
201506 0.099 238.638 0.127
201509 1.823 237.945 2.338
201512 0.185 236.525 0.239
201603 0.188 238.132 0.241
201606 0.191 241.018 0.242
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.118 246.819 0.146
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.382 252.439 0.462
201812 0.003 251.233 0.004
201903 0.038 254.202 0.046
201906 0.005 256.143 0.006
201909 0.006 256.759 0.007
201912 0.005 256.974 0.006
202003 0.007 258.115 0.008
202006 0.006 257.797 0.007
202009 0.008 260.280 0.009
202012 0.007 260.474 0.008
202103 0.006 264.877 0.007
202106 0.006 271.696 0.007
202109 0.005 274.310 0.006
202112 0.005 278.802 0.005
202203 0.007 287.504 0.007
202206 0.008 296.311 0.008
202209 0.008 296.808 0.008
202212 0.006 296.797 0.006
202303 0.008 301.836 0.008
202306 0.006 305.109 0.006

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.15 mean?
Infinity Pharmaceuticals (INFIQ) has a Cyclically Adjusted Revenue per Share of $1.15 as of Jun. 2023. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Infinity Pharmaceuticals and its competitors.
Is Infinity Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Infinity Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $1.15. Overall, Infinity Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Infinity Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to CLCS and RVLPQ?
Infinity Pharmaceuticals' Cyclically Adjusted Revenue per Share of $1.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Infinity Pharmaceuticals and its competitors. Infinity Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinity Pharmaceuticals stock overvalued right now?
Infinity Pharmaceuticals (INFIQ) has a current Cyclically Adjusted Revenue per Share of $1.15. The current Cyclically Adjusted Revenue per Share is $1.15. Infinity Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Infinity Pharmaceuticals (INFIQ), the current Cyclically Adjusted Revenue per Share is $1.15 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infinity Pharmaceuticals Business Description

Address 1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
16GF Score

Get the complete analysis for INFIQ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price